Key Developments: Ark Therapeutics Group PLC (AKT.L)

AKT.L on London Stock Exchange

0.42GBp
8 May 2013
Price Change (% chg)

0.03p (+9.09%)
Prev Close
0.38p
Open
0.40p
Day's High
0.42p
Day's Low
0.40p
Volume
1,070,000
Avg. Vol
2,647,155
52-wk High
3.70p
52-wk Low
0.33p

Search Stocks

Latest Key Developments (Source: Significant Developments)

Ark Therapeutics Group plc Signs Letter Of Intent With EMD Millipore Corporation
Tuesday, 14 Aug 2012 02:00am EDT 

Ark Therapeutics Group plc announced that it has signed a non-binding letter of intent with EMD Millipore Corporation, USA (a division of Merck KGaA, Darmstadt, Germany) (EMD Millipore) to enter into a collaborative agreement in the field of viral based bioengineered vaccines and other live viral products manufacturing. Key elements of the collaboration focus on production optimization of viral based bioengineered vaccines and other live viral products for pilot and production scale and the installation of these processes at Ark's GMP manufacturing facility in Kuopio, Finland. Additionally, the parties plan to establish a GMP BSL-2 suite in the Kuopio facility equipped with EMD Millipore process technology to enable Ark's wider routine use of EMD Millipore process technology in its manufacturing services business.  Full Article

Ark Therapeutics Group plc Announces Appointment Of Chief Executive Officer
Thursday, 5 Jul 2012 02:00am EDT 

Ark Therapeutics Group plc announced that Dr David Venables has been appointed as Chief Executive Officer (CEO) with effect from August 1, 2012. Martyn Williams, who joined the Company in October 1998 as Finance Director and became CEO in mid 2010, will hand over to David and leave the Company on July 31, 2012.  Full Article

Ark Therapeutics Group plc Not To Recommend Dividend
Monday, 12 Mar 2012 03:00am EDT 

Ark Therapeutics Group plc announced that the Directors are unable to recommend the payment of a dividend (2010: GBP nil).  Full Article

Ark Therapeutics Group plc Receives US Patent
Wednesday, 8 Feb 2012 02:00am EST 

Ark Therapeutics Group plc announced that the United States Patent and Trademark Office has issued a Notice of Allowance in respect of a patent covering the structures of candidate compounds in Ark's Neuropilin-1 receptor small molecule antagonist programme. Formal grant of this patent is expected in two months.  Full Article

Ark Therapeutics Group plc Signs Manufacturing Agreement With University Of Glasgow
Thursday, 3 Nov 2011 03:00am EDT 

Ark Therapeutics Group plc announced that it has signed a manufacturing agreement with University of Glasgow's Institute of Cardiovascular and Medical Sciences under which Ark will provide full manufacturing and related services to support the development of the Institute's gene-therapy programme for the treatment of vein graft failure associated with coronary artery bypass surgery. The contract was awarded following Ark's success in an open competitive tender process under public body procurement rules. Ark will manufacture for University of Glasgow cGMP grade adenoviral vector expressing TIMP3 gene to be administered ex vivo to vein grafts at the time of coronary artery bypass surgery in the University's first-in-man Phase I/II trial to reduce vein graft failure. Financial details of the agreement were not disclosed.  Full Article

Ark Therapeutics Group plc And PsiOxus Therapeutics Enter Manufacturing Partnership
Monday, 12 Sep 2011 02:00am EDT 

Ark Therapeutics Group plc announced that it has signed a manufacturing partnership agreement with PsiOxus Therapeutics Ltd (PsiOxus) under which Ark will provide full manufacturing and related services to support the development of PsiOxus' ColoAd1 programme for the treatment of colorectal cancer. Ark will work with PsiOxus in providing oncolytic adenoviral material for IV administration in toxicological and Phase I/II clinical studies, utilising Ark's suspension based single use system (ATOSUS). Financial details of the agreement were not disclosed.  Full Article

Ark Therapeutics Group plc Receives Grant Of Up To EUR0.4 Million From Finnish Funding Agency For Technology And Innovation
Wednesday, 6 Jul 2011 02:00am EDT 

Ark Therapeutics Group plc announced that it has been awarded a grant of up to EUR0.4 million from Finnish Funding Agency for Technology and Innovation (TEKES) to support the further development of Ark's lentiviral vector production technology using baculoviruses (Baculo-lentiviral) to achieve the scale and GMP required for clinical use. Ark has also been awarded a EUR0.2 million grant from Finnish governmental organization Centre for Economic Development, Transport and the Environment (ELY-centre) to progress validation work in its GMP3 manufacturing facility in Kuopio.  Full Article

Ark Therapeutics Group plc Announces Notice of Allowance of US patents For Boehringer Ingelheim's compoundTelmisartan
Monday, 4 Jul 2011 02:00am EDT 

Ark Therapeutics Group plc announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance in respect of two patents for which certain rights have been assigned by Ark to Boehringer Ingelheim. The patents cover the use of Boehringer Ingelheim's compound Telmisartan for the prevention and treatment of stroke and the prevention of myocardial infarction related heart damage. Formal grant of these patents by the USPTO is expected in the next two months and will trigger significant milestone payments to Ark under the license agreement which Ark and Boehringer Ingelheim entered into in 2005.  Full Article

  • Previous
  • Next

Ark Therapeutics Group PLC News

UPDATE 1-Ark Therapeutics sells two units; shares plunge

* Shares fall as much as 61 pct (Adds background; updates share movement)

» More AKT.L News

Earnings vs. Estimates

» More Financials
Search Stocks